Jeffrey F Patton MD

CEO, Tennessee Oncology

397 Wallace RdSte C201Nashville, TN 37211
Phone+1 615-333-2481
Fax+1 615-781-3923

Dr. Patton is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patton's full profile Already have an account?

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1988 - 1991
Eastern Virginia Medical SchoolClass of 1988

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TN State Medical License 1996 - 2024
NC State Medical License 1989 - 1992

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017

Clinical Trials

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer Start of enrollment: 2008 Nov 01
Completed
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma Start of enrollment: 2009 May 01
Completed
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting Start of enrollment: 2008 Jan 01
Completed

Publications & Presentations

PubMed

14 citations
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
Johanna C. Bendell, Suzanne F. Jones, Lowell L. Hart, Shubham Pant, Adil Moyhuddin
Cancer Investigation. 2015-10-13
18 citations
A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer
Denise A. Yardley, Michael McCleod, Fred Schreiber, Patrick Murphy, J. F. Patton
Cancer Investigation. 2010-10-11
6 citations
Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
David R. Spigel, John D. Hainsworth, John H. Barton, J. F. Patton, John D. Zubkus
Journal of Thoracic Oncology. 2010-06-01